On March 2, seven members of Congress who are also physicians sent a letter to HHS urging the department to revise its COVID-19 vaccine emergency use authorization to be “based on all available clinical data.” The lawmakers said such a revision could lead to an endorsement of single-dose regimens for Pfizer and Moderna vaccines, which could speed up the nation’s COVID-19 vaccination effort.
However, government scientists have said there is not enough reliable data to justify single-dose regimens for Pfizer and Moderna vaccines. They said although single doses of these vaccines may offer short term-protection from COVID-19, they are designed to give recipients long-term protection only after two doses, according to the Journal.
“It is essential that these vaccines be used as authorized by FDA in order to prevent Covid-19 and related hospitalizations and death,” Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research, told the Journal.
More articles on pharmacy:
Amgen acquires cancer drugmaker for $1.9B
Moderna vaccine causing delayed rash in some recipients, small study says
Drugmakers studying how to administer COVID-19 vaccines without a needle
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
